Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

Patrick J Hayden; Dirk-Jan Eikema; Liesbeth C de Wreede; Linda Koster; Nicolaus Kröger; Hermann Einsele; Monique Minnema; Alida Dominietto; Michael Potter; Jacob Passweg; Arancha Bermúdez; Stephanie Nguyen-Quoc; Uwe Platzbecker; Johanna Tischer; Fabio Ciceri; Joan Hendrik Veelken; Per Ljungman; Nicolaas Schaap; Edouard Forcade; Angelo Michele Carella; Virginie Gandemer; William Arcese; Adrian Bloor; Attilio Olivieri; Laure Vincent; Meral Beksac; Stefan Schönland; Ibrahim Yakoub-Agha

doi:10.1038/s41409-021-01286-x

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

Patrick J Hayden
, Dirk-Jan Eikema
, Liesbeth C de Wreede
, Linda Koster
, Nicolaus Kröger
, Hermann Einsele
, Monique Minnema
, Alida Dominietto
, Michael Potter
, Jacob Passweg
, Arancha Bermúdez
, Stephanie Nguyen-Quoc
, Uwe Platzbecker
, Johanna Tischer
, Fabio Ciceri
, Joan Hendrik Veelken
, Per Ljungman
, Nicolaas Schaap
, Edouard Forcade
, Angelo Michele Carella

Virginie Gandemer, William Arcese, Adrian Bloor, Attilio Olivieri, Laure Vincent, Meral Beksac, Stefan Schönland, Ibrahim Yakoub-Agha

Research output: Contribution to journal › Article › Academic › peer-review

13 Downloads (Pure)

Abstract

The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30-46%) at 2 years and 25% (17-32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24-46%); Others 9% (0-17%), p < 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33-67%); Other 22% (8-36%), p = 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21-40%) vs. 10% (1-20%), P = 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24-0.67), p < 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.

Original language	English
Pages (from-to)	2367-2381
Number of pages	15
Journal	Bone Marrow Transplantation
Volume	56
Issue number	10
Early online date	11 May 2021
DOIs	https://doi.org/10.1038/s41409-021-01286-x
Publication status	Published - Oct 2021

Access to Document

10.1038/s41409-021-01286-xLicence: CC BY

s41409-021-01286-xFinal published version, 1.05 MBLicence: CC BY

Cite this

Hayden, P. J., Eikema, D.-J., de Wreede, L. C., Koster, L., Kröger, N., Einsele, H., Minnema, M., Dominietto, A., Potter, M., Passweg, J., Bermúdez, A., Nguyen-Quoc, S., Platzbecker, U., Tischer, J., Ciceri, F., Veelken, J. H., Ljungman, P., Schaap, N., Forcade, E., ... Yakoub-Agha, I. (2021). Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party. Bone Marrow Transplantation, 56(10), 2367-2381. https://doi.org/10.1038/s41409-021-01286-x

@article{8d59b318f2d647ac83aa00c3032e9eab,

title = "Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party",

abstract = "The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38\% (30-46\%) at 2 years and 25\% (17-32\%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35\% (24-46\%); Others 9\% (0-17\%), p < 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50\% (33-67\%); Other 22\% (8-36\%), p = 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31\% (21-40\%) vs. 10\% (1-20\%), P = 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24-0.67), p < 0.001). In the graft failure group, OS was 41\% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.",

author = "Hayden, \{Patrick J\} and Dirk-Jan Eikema and \{de Wreede\}, \{Liesbeth C\} and Linda Koster and Nicolaus Kr{\"o}ger and Hermann Einsele and Monique Minnema and Alida Dominietto and Michael Potter and Jacob Passweg and Arancha Berm{\'u}dez and Stephanie Nguyen-Quoc and Uwe Platzbecker and Johanna Tischer and Fabio Ciceri and Veelken, \{Joan Hendrik\} and Per Ljungman and Nicolaas Schaap and Edouard Forcade and Carella, \{Angelo Michele\} and Virginie Gandemer and William Arcese and Adrian Bloor and Attilio Olivieri and Laure Vincent and Meral Beksac and Stefan Sch{\"o}nland and Ibrahim Yakoub-Agha",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = oct,

doi = "10.1038/s41409-021-01286-x",

language = "English",

volume = "56",

pages = "2367--2381",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Springer Nature",

number = "10",

}

Hayden, PJ, Eikema, D-J, de Wreede, LC, Koster, L, Kröger, N, Einsele, H, Minnema, M, Dominietto, A, Potter, M, Passweg, J, Bermúdez, A, Nguyen-Quoc, S, Platzbecker, U, Tischer, J, Ciceri, F, Veelken, JH, Ljungman, P, Schaap, N, Forcade, E, Carella, AM, Gandemer, V, Arcese, W, Bloor, A, Olivieri, A, Vincent, L, Beksac, M, Schönland, S & Yakoub-Agha, I 2021, 'Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party', Bone Marrow Transplantation, vol. 56, no. 10, pp. 2367-2381. https://doi.org/10.1038/s41409-021-01286-x

TY - JOUR

T1 - Second allogeneic transplants for multiple myeloma

T2 - a report from the EBMT Chronic Malignancies Working Party

AU - Hayden, Patrick J

AU - Eikema, Dirk-Jan

AU - de Wreede, Liesbeth C

AU - Koster, Linda

AU - Kröger, Nicolaus

AU - Einsele, Hermann

AU - Minnema, Monique

AU - Dominietto, Alida

AU - Potter, Michael

AU - Passweg, Jacob

AU - Bermúdez, Arancha

AU - Nguyen-Quoc, Stephanie

AU - Platzbecker, Uwe

AU - Tischer, Johanna

AU - Ciceri, Fabio

AU - Veelken, Joan Hendrik

AU - Ljungman, Per

AU - Schaap, Nicolaas

AU - Forcade, Edouard

AU - Carella, Angelo Michele

AU - Gandemer, Virginie

AU - Arcese, William

AU - Bloor, Adrian

AU - Olivieri, Attilio

AU - Vincent, Laure

AU - Beksac, Meral

AU - Schönland, Stefan

AU - Yakoub-Agha, Ibrahim

PY - 2021/10

Y1 - 2021/10

N2 - The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30-46%) at 2 years and 25% (17-32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24-46%); Others 9% (0-17%), p < 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33-67%); Other 22% (8-36%), p = 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21-40%) vs. 10% (1-20%), P = 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24-0.67), p < 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.

AB - The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30-46%) at 2 years and 25% (17-32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24-46%); Others 9% (0-17%), p < 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33-67%); Other 22% (8-36%), p = 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21-40%) vs. 10% (1-20%), P = 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24-0.67), p < 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.

UR - https://www.scopus.com/pages/publications/85105797196

U2 - 10.1038/s41409-021-01286-x

DO - 10.1038/s41409-021-01286-x

M3 - Article

C2 - 33976382

SN - 0268-3369

VL - 56

SP - 2367

EP - 2381

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 10

ER -

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

Abstract

Access to Document

Other files and links

Fingerprint

Cite this